Table 3.
Mean (SD) Monthly Health Care Cost in the 12 Months Pre-Index and During Lapatinib Treatment Period and Post-Lapatinib Treatment Period (N = 666).
| Follow-Up Period |
||||
|---|---|---|---|---|
| Measure | 12-Month Pre-Index Period | Lapatinib Treatment | Post Lapatinib Treatment | All |
| Utilization | ||||
| No. of physicians’ office or outpatient hospital visits | 6.09 (3.04) | 5.45 (3.49) | 4.55 (3.90) | 5.22 (3.12) |
| No. of hospitalizations | 0.05 (0.08) | 0.09 (0.19) | 0.15 (0.32) | 0.10 (0.17) |
| No. of inpatient days | 0.24 (0.52) | 0.53 (1.39) | 0.96 (2.52) | 0.64 (1.30) |
| Costs, $ | ||||
| Lapatinib | 0 (0) | 2097 (877) | 0 (0) | 1469 (1031) |
| Trastuzumab | 2762 (2020) | 722 (1731) | 1166 (2134) | 924 (1556) |
| Chemotherapy | 1355 (1898) | 1496 (1698) | 1437 (2729) | 1543 (1805) |
| Chemotherapy administration | 508 (447) | 189 (298) | 326 (516) | 249 (343) |
| Other | 5446 (4680) | 5564 (7198) | 6880 (9726) | 5973 (5765) |
| Total | 10 071 (6056) | 10 067 (7695) | 9809 (10 853) | 10 158 (6468) |
| Total excluding lapatinib | 10 071 (6056) | 7970 (7734) | 9809 (10 853) | 8689 (6526) |
Abbreviation: SD, standard deviation.